233 related articles for article (PubMed ID: 16228105)
1. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.
Ringe JD; Dorst A; Faber H
Osteoporos Int; 2005 Dec; 16(12):2063-8. PubMed ID: 16228105
[TBL] [Abstract][Full Text] [Related]
2. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
3. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Ibach K; Preuss J
Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
[TBL] [Abstract][Full Text] [Related]
6. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
7. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
Ringe JD; Dorst A; Faber H; Ibach K; Sorenson F
Osteoporos Int; 2003 Oct; 14(10):801-7. PubMed ID: 14610641
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
9. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
10. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.
Ringe JD; Body JJ
Clin Exp Rheumatol; 2007; 25(5):766-74. PubMed ID: 18078631
[TBL] [Abstract][Full Text] [Related]
11. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
12. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H;
Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
15. Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
Klaus J; Reinshagen M; Herdt K; Adler G; von Boyen GB; von Tirpitz C
J Gastrointestin Liver Dis; 2011 Jun; 20(2):141-8. PubMed ID: 21725510
[TBL] [Abstract][Full Text] [Related]
16. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate].
Hashimoto J
Clin Calcium; 2007 Jan; 17(1):11-7. PubMed ID: 17211088
[TBL] [Abstract][Full Text] [Related]
18. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
19. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]